Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK

Zalmai HakimiMedical Affairs Department, Astellas Pharma Europe B.V, Leiden, The NetherlandsCorrespondence[email protected]
View further author information

Con KelleherDepartment of Obstetrics and Gynecology, Guy’s and St. Thomas’ NHS Foundation Trust, London, UKView further author information

Samuel AballéaHealth Economics and Outcomes Research Department, Creativ-Ceutical SARL, Paris, FranceView further author information

Khaled MamanHealth Economics and Outcomes Research Department, Creativ-Ceutical Ltd, London, UKView further author information

Jameel NazirMedical Affairs Department, Astellas Pharma Europe Ltd, Chertsey, UKView further author information

Colette MankowskiMedical Affairs Department, Astellas Pharma Europe Ltd, Chertsey, UKView further author information

Isaac OdeyemiMedical Affairs Department, Astellas Pharma Europe Ltd, Chertsey, UKView further author information

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.